Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 438403, 8 pages
http://dx.doi.org/10.1155/2015/438403
Research Article

5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure

1Universities of Giessen and Marburg Lung Centre (UGMLC), Aulweg 130, 35392 Giessen, Germany
2German Center for Lung Research (DZL), 35392 Giessen, Germany
3Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany

Received 22 August 2014; Accepted 28 October 2014

Academic Editor: Shiro Mizuno

Copyright © 2015 Wiebke Janssen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure,” Circulation, vol. 114, no. 17, pp. 1883–1891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. J. Bogaard, K. Abe, A. V. Noordegmaf, and N. F. Voelkel, “The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension,” Chest, vol. 135, no. 3, pp. 794–804, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Guglin and S. Verma, “Right side of heart failure,” Heart Failure Reviews, vol. 17, no. 3, pp. 511–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Mann and F. Oakley, “Serotonin paracrine signaling in tissue fibrosis,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1832, no. 7, pp. 905–910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. K.-G. Shyu, “Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?” Circulation Research, vol. 104, pp. 1–3, 2009. View at Google Scholar
  6. O. Lairez, T. Cognet, S. Schaak et al., “Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice,” Journal of Neural Transmission, vol. 120, no. 6, pp. 927–935, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. C. G. Nebigil, D.-S. Choi, A. Dierich et al., “Serotonin 2B receptor is required for heart development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9508–9513, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. C. G. Nebigil, P. Hickel, N. Messaddeq et al., “Ablation of serotonin 5-HT2B receptors in mice leads to abnormal cardiac structure and function,” Circulation, vol. 103, no. 24, pp. 2973–2979, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Jaffré, J. Callebert, A. Sarre et al., “Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1β, and tumor necrosis factor-α cytokine production by ventricular fibroblasts,” Circulation, vol. 110, no. 8, pp. 969–974, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Monassier, M.-A. Laplante, F. Jaffré, P. Bousquet, L. Maroteaux, and J. de Champlain, “Serotonin 5-HT2B receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice,” Hypertension, vol. 52, no. 2, pp. 301–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Jaffré, P. Bonnin, J. Callebert et al., “Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy,” Circulation Research, vol. 104, no. 1, pp. 113–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Abenhaim, Y. Moride, F. Brenot et al., “Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group,” The New England Journal of Medicine, vol. 335, pp. 609–619, 1996. View at Google Scholar
  13. D. Kosanovic and R. Schermuly, “Are tyrosine kinase inhibitors the better serotonin inhibitors?” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 1, pp. 4–5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Thomas, L. Ciuclan, M. J. Hussey, and N. J. Press, “Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension,” Pharmacology and Therapeutics, vol. 138, no. 3, pp. 409–417, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Liu, H.-Y. Tian, X.-L. Yan, F.-L. Fan, W.-P. Wang, and J.-L. Han, “Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension,” Experimental Lung Research, vol. 39, no. 2, pp. 70–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Ciuclan, M. J. Hussey, V. Burton et al., “Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression,” The American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 1, pp. 78–89, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Novoyatleva, Y. Schymura, W. Janssen et al., “Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction,” Basic Research in Cardiology, vol. 108, no. 2, article 325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. M. Budev, A. C. Arroliga, H. P. Wiedemann, and R. A. Matthay, “Cor pulmonale: an overview,” Seminars in Respiratory and Critical Care Medicine, vol. 24, no. 3, pp. 233–243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. L. R. Frumkin, “The pharmacological treatment of pulmonary arterial hypertension,” Pharmacological Reviews, vol. 64, no. 3, pp. 583–620, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-A. Ghofrani, N. Galiè, F. Grimminger et al., “Riociguat for the treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 369, no. 4, pp. 330–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. E. Ventetuolo and J. R. Klinger, “WHO Group 1 pulmonary arterial hypertension: current and investigative therapies,” Progress in Cardiovascular Diseases, vol. 55, no. 2, pp. 89–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Schäfer, P. Ellinghaus, W. Janssen et al., “Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling,” Cardiovascular Research, vol. 82, no. 1, pp. 30–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Herve, L. Drouet, C. Dosquet et al., “Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin,” The American Journal of Medicine, vol. 89, no. 1, pp. 117–120, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Hervé, J.-M. Launay, M.-L. Scrobohaci et al., “Increased plasma serotonin in primary pulmonary hypertension,” The American Journal of Medicine, vol. 99, no. 3, pp. 249–254, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Humbert, P. Labrune, O. Sitbon et al., “Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis,” European Respiratory Journal, vol. 20, no. 1, pp. 59–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Kéreveur, J. Callebert, M. Humbert et al., “High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (Prostacyclin) therapy,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 10, pp. 2233–2239, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Dumitrascu, C. Kulcke, M. Königshoff et al., “Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats,” European Respiratory Journal, vol. 37, no. 5, pp. 1104–1118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J.-M. Launay, P. Hervé, K. Peoc'h et al., “Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension,” Nature Medicine, vol. 8, no. 10, pp. 1129–1135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Hironaka, M. Hongo, A. Sakai et al., “Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats,” Cardiovascular Research, vol. 60, no. 3, pp. 692–699, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Kanai, S. Hori, T. Tanaka et al., “Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats,” Cardiovascular Research, vol. 27, no. 9, pp. 1619–1623, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Miyata, M. Ito, T. Sasajima, H. Ohira, Y. Sato, and R. Kasukawa, “Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist,” Lung, vol. 178, no. 2, pp. 63–73, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Jähnichen, R. Horowski, and H. H. Pertz, “Agonism at 5-HT2B receptors is not a class effect of the ergolines,” European Journal of Pharmacology, vol. 513, no. 3, pp. 225–228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Kojonazarov, H. Luitel, A. Sydykov et al., “The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy,” Pulmonary Circulation, vol. 3, no. 4, pp. 926–935, 2013. View at Google Scholar
  34. P. R. Buskohl, M. L. Sun, R. P. Thompson, and J. T. Butcher, “Serotonin potentiates transforming growth factor-beta3 induced biomechanical remodeling in avian embryonic atrioventricular valves,” PLoS ONE, vol. 7, no. 8, Article ID e42527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Kren, E. Eich, and H. H. Pertz, “Pergolide, terguride and N,N'-spacerlinked oligomers of both interact with 5-HT2A receptors of rat tail artery,” Physiological Research, vol. 53, pp. 35–43, 2004. View at Google Scholar
  36. F. Jantschak, J. Brosda, R. T. Franke et al., “Pharmacological profile of 2-bromoterguride at human dopamine D 2, porcine serotonin 5-hydroxytryptamine 2A, and α 2C-adrenergic receptors, and its antipsychotic-like effects in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 347, no. 1, pp. 57–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Ciccarelli and F. Camanni, “Diagnosis and drug therapy of prolactinoma,” Drugs, vol. 51, no. 6, pp. 954–965, 1996. View at Publisher · View at Google Scholar · View at Scopus